Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome
- 24 September 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (13) , 2753-2763
- https://doi.org/10.1182/blood-2008-11-190330
Abstract
Down syndrome (DS) children have a unique genetic susceptibility to develop leukemia, in particular, acute megakaryocytic leukemia (AMkL) associated with somatic GATA1 mutations. The study of this genetic susceptibility with the use of DS as a model of leukemogenesis has broad applicability to the understanding of leukemia in children overall. On the basis of the role of GATA1 mutations in DS AMkL, we analyzed the mutational spectrum of GATA1 mutations to begin elucidating possible mechanisms by which these sequence alterations arise. Mutational analysis revealed a predominance of small insertion/deletion, duplication, and base substitution mutations, including G:C>T:A, G:C>A:T, and A:T>G:C. This mutational spectrum points to potential oxidative stress and aberrant folate metabolism secondary to genes on chromosome 21 (eg, cystathionine-β-synthase, superoxide dismutase) as potential causes of GATA1 mutations. Furthermore, DNA repair capacity evaluated in DS and non-DS patient samples provided evidence that the base excision repair pathway is compromised in DS tissues, suggesting that inability to repair DNA damage also may play a critical role in the unique susceptibility of DS children to develop leukemia. A model of leukemogenesis in DS is proposed in which mutagenesis is driven by cystathionine-β-synthase overexpression and altered folate homeostasis that becomes fixed as the ability to repair DNA damage is compromised.This publication has 61 references indexed in Scilit:
- Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalisBritish Journal of Haematology, 2008
- A sensitive biochemical assay for the detection of uracilEnvironmental and Molecular Mutagenesis, 2005
- Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agentOncogene, 2004
- Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemiaAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literatureUltrasound in Obstetrics & Gynecology, 2003
- Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21Ultrasound in Obstetrics & Gynecology, 2001
- In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndromeBritish Journal of Haematology, 1995
- EXCESSIVE CHEMOTHERAPY-RELATED MYELOTOXICITY IN CHILDREN WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKAEMIAThe Lancet, 1986
- Deoxyuridine misincorporation causes site-specific mutational lesions in the lacI gene of Escherichia coliMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1986
- Effect of the variations of S-adenosyl--methionine liver content on fat accumulation and ethanol metabolism in ethanol-intoxicated ratsToxicology and Applied Pharmacology, 1986